• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of applied laboratory medicine. >Influence of Warfarin Therapy on Prothrombin Production and Its Posttranslational Modifications
【24h】

Influence of Warfarin Therapy on Prothrombin Production and Its Posttranslational Modifications

机译：华法林治疗对凝血酶原的影响生产及其转译后的修改

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Protein induced by vitamin Kabsence-II (PIVKA-II) is produced by the liver during hepatoma and upon warfarin administration. Those patients have disturbed protein synthesis and glycosylation in the liver. This decreases the number of c-carboxyglutamyl (Gla) residues on prothrombin, converting prothrombin into PIVKA-II. The mechanism of this conversion, however, is not clearly understood.Methods: Prothrombin was isolated from healthy and warfarin-treated individuals whose liver function of protein production was quantitatively normal. Glycan structures in the purified prothrombin containing PIVKA-II were qualitatively analyzed by high performance liquid chromatography after labeling the glycan with fluoro-phore 2-aminobenzamide.Results: The concentration of PIVKA-II was significantly higher in the warfarin-treated individuals than in the healthy individuals (P< 0.001). Although protein production in the liver was normal in both groups, the concentration of prothrombin was lower in the warfarin-treated individuals than in the healthy individuals (P< 0.001). The main glycan was A2 in the healthy and warfarin-treated individuals (86.6 64.4% and 85.6 63.4%, respectively). Eight types of glycan were characterized in both groups, although generation of PIVKA-II in the warfarin-treated individuals did not lead to variation in glycosylation of prothrombin.Conclusions: Warfarin therapy leads to lower amounts of prothrombin and Gla residues within prothrombin without exerting qualitative and quantitative change in glycan profile and protein synthetic function in the liver.
机译：背景:维生素Kabsence-II蛋白质引起的(PIVKA-II)是由肝脏中肝癌和华法林管理。病人干扰蛋白质合成肝脏中糖基化。c-carboxyglutamyl (Gla)残留凝血酶原凝血酶原转化为PIVKA-II。然而,并不清楚。凝血酶原从健康和孤立warfarin-treated个人的肝脏功能蛋白质的定量生产正常。纯化多糖结构的凝血酶原包含PIVKA-II进行了定性分析通过高效液相色谱法标签与fluoro-phore多糖2-aminobenzamide。PIVKA-II显著更高warfarin-treated个人健康个人(P < 0.001)。生产在肝脏在这两方面都是正常的组,凝血酶原的浓度warfarin-treated个体比低健康人(P < 0.001)。多糖是健康warfarin-treated A2个人(86.6 - 64.4%和85.6 - 63.4%,分别)。两组特征,虽然一代warfarin-treated PIVKA-II的个人没有导致糖基化变化的凝血酶原。低凝血酶原和杯子残留物在凝血酶原没有施加定性聚糖简介,和定量变化肝脏中蛋白质合成功能。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号